Califf Gets Unanimous Committee Vote Supporting FDA Commissioner Bid
This article was originally published in Clinica
After being thoroughly questioned, Robert Califf won a unanimous vote in support of his bid to become the next FDA commissioner from the Senate Health, Education, Labor and Pensions Committee on Jan. 12. Califf, who currently serves as FDA's deputy commissioner for medical products and tobacco, still requires full Senate approval and is likely to find some challenges there.
You may also be interested in...
Robert Califf’s nomination to be the next US FDA commissioner squeaked out of the Senate health committee, but a significant number of Republicans are against his confirmation over the agency’s recent decisions on abortion drugs.
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker